{"id":"NCT01244828","sponsor":"Organon and Co","briefTitle":"Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)","officialTitle":"Long-term Study of Asenapine in Subjects With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (Protocol P06238)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-05","primaryCompletion":"2014-08-21","completion":"2014-08-21","firstPosted":"2010-11-19","resultsPosted":"2015-08-26","lastUpdate":"2024-05-28"},"enrollment":157,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Asenapine","otherNames":[]}],"arms":[{"label":"Asenapine","type":"EXPERIMENTAL"}],"summary":"This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple antipsychotic drugs, treatment refractory, or elderly participants with schizophrenia. The treatment period is up to 52 weeks.","primaryOutcome":{"measure":"Change From Baseline in Weight at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Asenapine","deltaMin":0.25,"sd":5.23}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":19},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":157},"commonTop":["Nasopharyngitis","Weight increased","Somnolence","Hypoaesthesia oral","Schizophrenia"]}}